• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALMS

    Alumis Inc.

    Subscribe to $ALMS
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Alumis Inc.

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    7/23/2024$36.00Overweight
    Morgan Stanley
    See more ratings

    Alumis Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Alumis with a new price target

      Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

      1/30/25 7:47:22 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Alumis with a new price target

      Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

      10/31/24 6:14:08 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Alumis with a new price target

      H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

      10/17/24 7:14:37 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Alumis

      Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight

      7/23/24 7:40:57 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Alumis with a new price target

      Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00

      7/23/24 6:42:58 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Alumis with a new price target

      Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00

      7/23/24 6:42:37 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Alumis with a new price target

      Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00

      7/23/24 6:19:38 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Akkaraju Srinivas was granted 1,214,582 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 8:47:53 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ayurmaya Capital Management Company, Lp was granted 4,493,741 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:20:51 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Machado Patrick was granted 7,064 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:05:20 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Tetrault Lynn A.

      3 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:03:24 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:59 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:12 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:47:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Akkaraju Srinivas bought $1,477,312 worth of shares (320,290 units at $4.61) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 6:52:45 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Colowick Alan bought $129,544 worth of shares (18,404 units at $7.04) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      4/3/25 6:05:40 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and Chairman Babler Martin bought $100,733 worth of shares (15,650 units at $6.44) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      4/3/25 6:05:05 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 8:49:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 4:16:27 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ALUMIS INC. (0001847367) (Filer)

      5/21/25 9:15:55 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ALUMIS INC. (0001847367) (Filer)

      5/19/25 4:05:21 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alumis Inc.

      10-Q - ALUMIS INC. (0001847367) (Filer)

      5/14/25 4:32:03 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALUMIS INC. (0001847367) (Filer)

      5/14/25 4:11:02 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alumis Inc.

      EFFECT - ALUMIS INC. (0001847367) (Filer)

      4/24/25 12:15:13 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Alumis Inc.

      424B3 - ALUMIS INC. (0001847367) (Filer)

      4/23/25 4:13:04 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Alumis Inc.

      10-K/A - ALUMIS INC. (0001847367) (Filer)

      4/23/25 4:10:23 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-4 filed by Alumis Inc.

      S-4 - ALUMIS INC. (0001847367) (Filer)

      4/21/25 5:26:08 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:59 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:12 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:47:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Akkaraju Srinivas bought $1,477,312 worth of shares (320,290 units at $4.61) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 6:52:45 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Colowick Alan bought $129,544 worth of shares (18,404 units at $7.04) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      4/3/25 6:05:40 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and Chairman Babler Martin bought $100,733 worth of shares (15,650 units at $6.44) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      4/3/25 6:05:05 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Akkaraju Srinivas bought $25,000,000 worth of shares (1,562,500 units at $16.00) (SEC Form 4)

      4/A - ALUMIS INC. (0001847367) (Issuer)

      8/27/24 4:10:05 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc converted options into 11,476,484 shares and bought $40,000,000 worth of shares (2,500,000 units at $16.00) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      7/3/24 9:31:39 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management V, Llc converted options into 11,476,484 shares and bought $40,000,000 worth of shares (2,500,000 units at $16.00) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      7/3/24 9:30:57 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tananbaum James B. converted options into 11,476,484 shares and bought $40,000,000 worth of shares (2,500,000 units at $16.00) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      7/3/24 9:30:10 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis Completes Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. "We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis' differentiated late-stage portfolio and develop transformative th

      5/21/25 9:10:51 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

      SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. "We're seeing strong momentum across our development programs, with our team continuing to execute effectively following a productive first quarter of 2025," said Martin Babler, President and Chief Executive Officer of Alumis. "This includes advancement of the ongoing

      5/14/25 4:05:00 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Stockholders Approve Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

      ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

      5/6/25 4:30:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

      Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (NASDAQ:ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee (the "Transaction Committee"), said, "The AC

      5/1/25 1:30:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN Announce Amended Merger Agreement

      ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GL

      4/21/25 6:30:00 AM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

      Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in

      4/4/25 4:34:51 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

      - Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmac

      3/25/25 2:30:00 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

      – Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 – SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEW

      3/19/25 4:05:00 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. Financials

    Live finance-specific insights

    See more
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alumis Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      8/27/24 4:20:38 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alumis Inc.

      SC 13G - ALUMIS INC. (0001847367) (Subject)

      7/11/24 4:30:21 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      7/5/24 9:30:17 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      7/3/24 4:47:32 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care